- Conditions
- Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
- Interventions
- Sublingual film containing Igalmi
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–20
of 20
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreatic Cancer
- Interventions
- Talabostat Mesylate
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Agitation, Dementia
- Interventions
- BXCL501, Placebo film
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 3
- States / cities
- North Miami, Florida • Springfield, Massachusetts • Toms River, New Jersey
- Conditions
- Opioid Withdrawal
- Interventions
- Dexmedetomidine, Placebo
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Miami Lakes, Florida • Marlton, New Jersey • New York, New York
- Conditions
- Agitation, Delirium
- Interventions
- BXCL501, Placebo film
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Psychomotor Agitation
- Interventions
- BXCL501 Sublingual Film
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 5
- States / cities
- Chino, California • Oceanside, California • Orange, California + 2 more
- Conditions
- Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
- Interventions
- Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
- Drug
- Lead sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Interventions
- BXCL501, Matching Placebo
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 24
- States / cities
- Bellflower, California • Cerritos, California • Culver City, California + 19 more
- Conditions
- Agitation,Psychomotor, Dementia
- Interventions
- Sublingual film containing Dexmedetomidine, Sublingual Placebo Film
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Homestead, Florida • Miami Lakes, Florida • Springfield, Massachusetts + 2 more
- Conditions
- Agitation, Dementia
- Interventions
- BXCL501, Matching Placebo
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Los Alamitos, California • Daytona Beach, Florida • Maitland, Florida + 4 more
- Conditions
- Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
- Interventions
- Sublingual film containing dexmedetomidine (BXCL501), Placebo Film
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- BXCL701, Pembrolizumab
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Prostate Cancer, Neuroendocrine Tumors, Small Cell Carcinoma
- Interventions
- BXCL701 plus Pembrolizumab, BXCL701 monotherapy
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 9
- States / cities
- San Francisco, California • Denver, Colorado • New Haven, Connecticut + 6 more
- Conditions
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II
- Interventions
- BXCL501 80 Micrograms, Placebo Film, BXCL501 120 Micrograms, BXCL501 60 Micrograms
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Anaheim, California • Hialeah, Florida • Atlanta, Georgia + 2 more
- Conditions
- Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder
- Interventions
- Sublingual film containing Dexmedetomidine (BXCL501), Placebo Film
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more
- Conditions
- Opioid Use Disorder, Opioid Withdrawal
- Interventions
- BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo, Lofexidine (Positive Control)
- Drug · Other
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Eatontown, New Jersey • Marlton, New Jersey + 1 more
- Conditions
- Agitation, Dementia
- Interventions
- BXCL501, Matching Placebo
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Long Beach, California • Daytona Beach, Florida + 8 more
- Conditions
- Agitation, Schizophrenia
- Interventions
- Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film
- Drug
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 9 more
- Conditions
- Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
- Interventions
- Dexmedetomidine, Lorazepam 2 MG/ML
- Drug
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
- Interventions
- Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity
- Drug · Procedure · Behavioral
- Lead sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut